Arcturus Therapeutics Ltd (NASDAQ:ARCT) has been given an average rating of “Hold” by the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $4.06.
A number of analysts have recently weighed in on the company. Ladenburg Thalmann lowered Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 28th. ValuEngine lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, April 27th.
Shares of Arcturus Therapeutics traded up $0.15, reaching $7.15, during trading hours on Friday, Marketbeat Ratings reports. 2,501 shares of the company were exchanged, compared to its average volume of 30,234. Arcturus Therapeutics has a 1 year low of $4.78 and a 1 year high of $15.19.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.